Valsartan/sacubutril
Article Sidebar
Main Article Content
Abstract
Sacubitril Valsartan Sodium Salt Complex is a new fixed-dose oral medication combination of the Neprilysin inhibitor, Sacubitril and the angiotensin II receptor blocker (ARB), Valsartan. It purpose is to reduce the risk of cardiovascular death and hospitalization in patients with reduce ejection fraction heart failure. The most frequent adverse reaction is hyperkalemia and hypotension. It is necessary to obtain basic drug information in order to maximize utilization.
Article Details
References
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-35.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation [Internet].2013[cited 2019 Aug 12];128(16):e240-e327. Available from: https://www.ahajournals.org/doi/epub/10.1161/CIR.0b013e31829e8776
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005;111:2837-49.
Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, TristaniFE,et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study.N Engl J Med 1986;314:1547-52.
CohnJN, Johnson G,ZiescheS, Cobb F, Francis G, Felix T, etal. A comparison of enalapril with hydralazine-isosorbidedinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-10.
Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am CollCardiol 2015;65:1029-41.
McDowell G, Nicholls DP. The therapeutic potential of candoxatril, a neutral endopeptidase inhibitor, in humans.Cardiovasc Drug Rev 2000;18:259-70.
Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation2002; 106:920-26.
Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103-11.